of Grodno State Medical University

ISSN (online): 2523-4722

Antithrombotic and anticoagulant therapy for atrial fibrillation

Show simple item record Dzeshka, M. S. Lip, G. Y. 2017-01-17T11:54:08Z 2017-01-17T11:54:08Z 2014-04
dc.identifier.citation Dzeshka, M. S. Antithrombotic and anticoagulant therapy for atrial fibrillation / M. S. Dzeshka, G. Y. Lip // Cardiology Clinics. – 2014. – Vol. 32, № 4. – P. 585–599. ru_RU
dc.description atrial fibrillation, stroke risk, bleeding risk, antithrombotic prophylaxis, oral anticoagulants, antiplatelet drugs ru_RU
dc.description.abstract Atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events. Hence, the vast majority of AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonist (VKA, e.g. warfarin) or non-VKA oral anticoagulants (NOACs, e.g. dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, stroke and bleeding risk assessment is an obligatory part of AF management and risk has to be weighed individually. Antiplatelet drugs (e.g. aspirin and clopidogrel) are inferior to OACs, both alone and in combination, with comparable risk of bleeding events. Exclusion of the left atrial appendage as major source of embolism in AF is an alternative option for stroke prevention in the few high risk patients with contraindications for anticoagulation. ru_RU
dc.language.iso en ru_RU
dc.title Antithrombotic and anticoagulant therapy for atrial fibrillation ru_RU
dc.type Article ru_RU

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account